Fed Sparks Profit T...
Health Care: Drugs
Immunomedics Inc. (IMMU: NASDAQ)
$3.36 0.08 | 2.44%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.36 |
| 52 Week High | 3.76 |
| 52 Week Low | 2.11 |
| Avg. Daily Vol. (Mil) | 0.45 |
| Beta (3 year) | 1.40 |
| Share Related Items | |
| Mkt Cap (Mil) | 277.94 |
| Shares Out (Mil) | 82.72 |
| Float (Mil) | 59.75 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.20 |
| Current Ratio | 5.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 60.91 |
| Price/Book | 6.33 |
| Price/Cash Flow | -24.90 |
| Per Share Data | |
| Earnings | -0.16 |
| Sales | 0.06 |
| Book Value | 0.53 |
| Cash Flow | -0.13 |
| Business Summary | |
|---|---|
| Immunomedics, Inc. is a biopharmaceutical company which is focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. | |
| General Information | |
| 300 American Road
Morris Plains, NJ 07950 |
|
| www.immunomedics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 124 | |
| CEO: Ms. Cynthia L. Sullivan | |
| Short Interest | |
| Current Month (Mil) | 8.44 |
| Previous Month (Mil) | 8.28 |
| Short Interest Ratio (Days) | 18.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -22.20 |
| Return on Investments | -27.00 |
| Profitability | |
| Gross Margin | 91.50 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with IMMU
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks to Watch Under $5
- Usertoms
- UserASCO 2010
- UserPortfolioRadical1
- UserPART 7 JPMorgan 28th Annual...
- Userinvestone
- Usermchish Portfolio 1
- UserASCO 2009 Nymph's Watch List.
Latest IMMU Headlines from TheStreet
- Biotech Stock Mailbag: Amarin, MannKind, Palatin 05.24.13 | 07:05 am
- Commit To Purchase Immunomedics At $2, Earn 22.8% Annualized 05.23.13 | 02:05 pm
- 3 Health Care Stocks Under $10 to Watch 05.09.13 | 09:05 pm
- Immunomedics Announces Third Quarter Fiscal 2013 Results And Clinical Program Developments 05.08.13 | 04:05 pm
- Immunomedics Announces Three New Patent Awards 05.07.13 | 08:05 am
- Immunomedics Announces Conference Call And Webcast For Third Quarter Fiscal 2013 Financial Results 04.25.13 | 08:04 am
- Immunomedics Develops T-Cell Redirecting Bispecific Antibodies As Potential Therapeutics For Solid And Liquid Tumors 04.10.13 | 08:04 am
- Immunomedics Reports First Results Of Labetuzumab-SN-38 In Colorectal Cancer 04.09.13 | 08:04 am
- Immunomedics Creates Novel Antibody-Cytokine Conjugates For Cancer Therapy 04.08.13 | 04:04 pm
- Immunomedics Announces Clivatuzumab-Based Blood Test Can Differentiate Between Pancreatic Cancer And Chronic Pancreatitis 04.08.13 | 01:04 pm
Press Releases for IMMU
Partner Headlines for IMMU
- Immunomedics Reports Clinically Meaningful Improvements for Lupus Patients Treated with Epratuzumab - Benzinga 11.13.12 | 09:11 am
- Merck Facing Too Much Competition In HIV Drug Push - Seeking Alpha 08.22.12 | 09:08 am
- CNS Cure Priority for UCB & Partner - Analyst Blog - Zacks 01.13.12 | 10:01 am
- Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune - Benzinga 12.12.11 | 01:12 pm
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography - Benzinga 06.08.11 | 04:06 pm
- UCB's Progress On-Track - Analyst Blog - Zacks 01.12.11 | 09:01 am
- Monoclonal Antibody Companies Command Premiums - Seeking Alpha 07.12.10 | 08:07 am
- Zacks Analyst Blog Highlights: Immunomedics, Human Genome, GlaxoSmithKline, CNOOC and Devon Energy - Press Releases - Zacks 06.22.10 | 09:06 am
- UPDATE 1-Immunomedics says lupus drug shows efficacy - Reuters 06.16.10 | 07:06 am
